Journal
PHARMACEUTICALS
Volume 14, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ph14101008
Keywords
triple-negative breast cancer; heterogeneity; molecular target; new drugs
Categories
Funding
- Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2021R1I1A1A01059173]
- Yonsei University College of Medicine [6-2014-0188]
- National Cancer Center Grant, Korea [NCC-1810861]
Ask authors/readers for more resources
Triple-negative breast cancer is a highly heterogeneous disease with limited therapeutic options as there are no appropriate targetable markers. Chemotherapy has been the mainstay treatment strategy, as tumors of this type do not respond to hormone therapy and HER2-targeted therapy.
Triple-negative breast cancer (TNBC) is one of the most heterogeneous diseases in solid tumors and has limited therapeutic options. Due to the lack of appropriate targetable markers, the mainstay therapeutic strategy for patients with TNBC has been chemotherapy for the last several decades. Indeed, TNBC tumors have no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 (HER2); therefore, they do not respond to hormone therapy and HER2-targeted therapy. In this review paper, the molecular heterogeneities, possible therapeutic targets, and recently approved and upcoming drugs for TNBC will be summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
